Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | BRAF | P15056 | 1/20 | 0.49 |
| ▸ | IKBKB | O14920 | 9/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84452 | 0.87 | MAPK1 (0.48) | MAPK1BRAFIKBKBPOLBSMN1; SMN2 | |
| SCHEMBL13524640 | 0.82 | HRH4 (0.42) | BRAFIKBKBSMN1; SMN2ALDH1A1CCNE1 | |
| SCHEMBL15181306 | 0.81 | MAPK1 (0.49) | MAPK1BRAFIKBKBPOLBSMN1; SMN2 | |
| SCHEMBL13524735 | 0.80 | BRAF (0.45) | MAPK1BRAFIKBKBMAPK8CDK2 | |
| SCHEMBL15185736 | 0.80 | BRAF (0.45) | MAPK1BRAFIKBKBMAPK8CDK2 | |
| SCHEMBL1090292 | 0.78 | CXCR4 (0.47) | MAPK1BRAFIKBKBPOLBALDH1A1 | |
| SCHEMBL1090644 | 0.77 | HRH4 (0.46) | MAPK1BRAFIKBKBPOLBALDH1A1 | |
| SCHEMBL13524608 | 0.76 | IKBKB (0.57) | IKBKBCCNE1CDK2 | |
| SCHEMBL14340205 | 0.75 | BRAF (0.86) | BRAFIKBKB | |
| SCHEMBL2745344 | 0.75 | BRAF (0.71) | MAPK1BRAFIKBKBMAPK8CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | MAPK1 215/4885BRAF 1/4885IKBKB 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.